Study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutatio

Phase 1

Recruiting

• Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma; Non-Small-Cell Lung, Carcinoma; Colorectal; KRAS G12C

• Registration Number: JPRN-jRCT2031200379
• Lead Sponsor: Hirano Takamitsu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors
- Prior treatment with a KRAS G12C inhibitor may be allowed for dose escalations of combinations

Exclusion Criteria

- Tumors harboring driver mutations that have approved therapies or tumors with known activating KRAS, NRAS, HRAS, BRAF or PTPN11 (SHP2) mutations, with exception of KRAS G12C mutations
- Active brain metastases
- Clinically significant cardiac disease or risk factors at screening

Study & Design

• Study Type: Interventional
• Study Design: Not specified